{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:06:10Z","timestamp":1740179170327,"version":"3.37.3"},"reference-count":113,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Cancer is a well-known risk factor of preventable thromboembolic disease. This study aims to provide guidance on the prevention and management of cancer-associated thrombosis (CT) that tailors prophylactic and therapeutic options for medical and surgical oncology patients presenting to health care settings in Saudi Arabia.<\/jats:p><jats:p>\n          Methods\u2003The present consensus was developed in concordance with the modified Delphi-based approach, which incorporates a face-to-face meeting between two voting rounds to gain experts' feedback on the proposed statements. All experts were either oncologists, hematologists, or hemato-oncologist with an active clinical and research profile in hemato-oncology.<\/jats:p><jats:p>\n          Results\u2003The experts highlighted that the comparatively high incidence of inherited thrombophilia among the Saudi population may account for a higher CT burden in the Kingdom than in other parts of the world. However, due to the lack of literature that assesses CT in Saudi Arabia, primary venous thromboembolism prophylaxis should be tailored according to a valid risk assessment of cancer patients and should be implemented in routine practice. For hospitalized medical oncology patients, the experts agreed that prophylaxis with low-molecular-weight heparin (LMWH) should be offered, regardless of the presence of acute illness. For ambulatory medical oncology patients, LMWH or direct oral anticoagulants (DOACs) prophylaxis should be offered for high-risk patients. Concerning surgical patients, they agreed that all oncology patients undergoing surgery should be offered thromboprophylaxis. In terms of secondary prophylaxis, the experts recommended continuing a prophylactic dose of anticoagulant (LMWH or DOAC), for an appropriate period depending on the cancer type and stage. Finally, they also provided a set of statements on management of CT in Saudi Arabia.<\/jats:p><jats:p>\n          Conclusion\u2003The present modified Delphi-based study combined the best available evidence and clinical experience with the current health care policies and settings in Saudi Arabia to build a consensus statement on the epidemiology, prevention, and management of CT.<\/jats:p>","DOI":"10.1055\/s-0042-1758856","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T23:29:58Z","timestamp":1673134198000},"page":"e14-e29","source":"Crossref","is-referenced-by-count":1,"title":["The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study"],"prefix":"10.1055","volume":"07","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1651-1158","authenticated-orcid":false,"given":"Mohammed","family":"Alsheef","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouki","family":"Bazarbashi","sequence":"additional","affiliation":[{"name":"College of Medicine, Al-Faisal University Medical Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Warsi","sequence":"additional","affiliation":[{"name":"Department of Haematology, Ministry of National Guard-Health Affairs, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia"},{"name":"Department of Medicine, Faculty of Medicine, Umm Alqura University, Makkah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras","family":"Alfraih","sequence":"additional","affiliation":[{"name":"College of Medicine, Al-Faisal University Medical Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdualkreem","family":"Almoomen","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Osman","sequence":"additional","affiliation":[{"name":"Pfizer Pharmaceuticals, Riyadh, Saudia Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Owaidah","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,1,7]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.beha.2012.06.007","article-title":"Venous thromboembolism: epidemiology and magnitude of the problem","volume":"25","author":"S Z Goldhaber","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11936-016-0445-y","article-title":"Cancer-associated venous thromboembolism","volume":"18","author":"H Elewa","year":"2016","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(01)00619-2","article-title":"Cancer and the prothrombotic state","volume":"3","author":"G Y Lip","year":"2002","journal-title":"Lancet Oncol"},{"key":"ref5","first-page":"1","volume-title":"Saudi Cancer Registry: Cancer Incidence Report Saudi Arabia 2014","author":"Z S Al-Shahrani","year":"2017"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0030-5073(73)90052-4","article-title":"A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups","volume":"9","author":"D H Gustafson","year":"1973","journal-title":"Organ Behav Hum Perform"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2106\/00004623-200301000-00001","article-title":"Introducing levels of evidence to the journal","volume":"85","author":"J G Wright","year":"2003","journal-title":"J Bone Joint Surg Am"},{"issue":"06","key":"ref10","first-page":"382","article-title":"Determination and quantification of content validity","volume":"35","author":"M R Lynn","year":"1986","journal-title":"Nurs Res"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"A J Walker","year":"2013","journal-title":"Eur J Cancer"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2006.01804.x","article-title":"Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study","volume":"4","author":"J W Blom","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"H K Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1160\/TH04-08-0506","article-title":"Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996","volume":"93","author":"R H White","year":"2005","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1161\/ATVBAHA.109.190827","article-title":"High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study","volume":"29","author":"R Vormittag","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"F Horsted","year":"2012","journal-title":"PLoS Med"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2010.05.012","article-title":"Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy","volume":"126","author":"G C Connolly","year":"2010","journal-title":"Thromb Res"},{"issue":"S 01","key":"ref18","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.028","article-title":"Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer","volume":"164","author":"G H Lyman","year":"2018","journal-title":"Thromb Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.thromres.2018.04.021","article-title":"Secular trends and etiologies of venous thromboembolism in Chinese from 2004 to 2016","volume":"166","author":"D Huang","year":"2018","journal-title":"Thromb Res"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1078155217730129","article-title":"Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants","volume":"25","author":"E M Uppuluri","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2005.04.2150","article-title":"Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival","volume":"24","author":"A Alcalay","year":"2006","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ygyno.2007.02.024","article-title":"Venous thromboembolism in ovarian cancer","volume":"105","author":"A O Rodriguez","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"A A Khorana","year":"2007","journal-title":"Cancer"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.amjmed.2005.06.058","article-title":"Incidence of venous thromboembolism in patients hospitalized with cancer","volume":"119","author":"P D Stein","year":"2006","journal-title":"Am J Med"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"J F Timp","year":"2013","journal-title":"Blood"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.7314\/APJCP.2012.13.4.1311","article-title":"Frequency, clinical pattern and outcome of thrombosis in cancer patients in Saudi Arabia","volume":"13","author":"A Aleem","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"A A Khorana","year":"2013","journal-title":"Cancer"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"A A Khorana","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.thromres.2018.02.012","article-title":"Cancer associated venous thromboembolism: incidence and impact on survival","volume":"164","author":"A M Brunson","year":"2018","journal-title":"Thromb Res"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.lungcan.2012.09.007","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer","volume":"78","author":"G C Connolly","year":"2012","journal-title":"Lung Cancer"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/jth.12408","article-title":"Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism","volume":"11","author":"O K\u00f6nigsbr\u00fcgge","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"G H Lyman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/annonc\/mdp354","article-title":"Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial","volume":"21","author":"M Mandal\u00e0","year":"2010","journal-title":"Ann Oncol"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdj068","article-title":"Risk factors for venous thromboembolic events in cancer patients","volume":"17","author":"K Kr\u00f6ger","year":"2006","journal-title":"Ann Oncol"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.thromres.2015.07.004","article-title":"Family history of venous thromboembolism and risk of hospitalized thromboembolism in cancer patients: a nationwide family study","volume":"136","author":"B Z\u00f6ller","year":"2015","journal-title":"Thromb Res"},{"issue":"13","key":"ref36","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jnci\/djq211","article-title":"Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer","volume":"102","author":"J E Garber","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.12778","article-title":"Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS)","volume":"13","author":"I Pabinger","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3324\/haematol.2016.147405","article-title":"Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism","volume":"101","author":"O V Gran","year":"2016","journal-title":"Haematologica"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2014.12.015","article-title":"Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study","volume":"26","author":"M Kovac","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","article-title":"Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006","volume":"103","author":"D P Cronin-Fenton","year":"2010","journal-title":"Br J Cancer"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/jcp.42.8.805","article-title":"Prevalence of pulmonary embolism at necropsy in patients with cancer","volume":"42","author":"E Svendsen","year":"1989","journal-title":"J Clin Pathol"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2006.07.4393","article-title":"Incidence of venous thromboembolism and the impact on survival in breast cancer patients","volume":"25","author":"H K Chew","year":"2007","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"J W Blom","year":"2005","journal-title":"JAMA"},{"issue":"08","key":"ref44","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3324\/haematol.2012.073338","article-title":"Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study","volume":"98","author":"B Dickmann","year":"2013","journal-title":"Haematologica"},{"issue":"31","key":"ref45","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1200\/JCO.2011.40.1810","article-title":"Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study","volume":"30","author":"J Ahlbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"24","key":"ref46","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"C Ay","year":"2010","journal-title":"Blood"},{"issue":"07","key":"ref47","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"C Ay","year":"2008","journal-title":"Blood"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.thromres.2015.06.036","article-title":"Characteristics and risk factors of cancer associated venous thromboembolism","volume":"136","author":"A S Faiz","year":"2015","journal-title":"Thromb Res"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"J A Heit","year":"2000","journal-title":"Arch Intern Med"},{"issue":"35","key":"ref50","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis","volume":"30","author":"S Seng","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"ref51","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"S R Nalluri","year":"2008","journal-title":"JAMA"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/asheducation-2014.1.410","article-title":"Flamethrowers: blood cells and cancer thrombosis risk","volume":"2014","author":"I Pabinger","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1538-7836.2009.03680.x","article-title":"High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"8","author":"R Simanek","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref54","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/icvts\/ivw158","article-title":"Comparison between Caprini and Padua risk assessment models for hospitalized medical patients at risk for venous thromboembolism: a retrospective study","volume":"23","author":"X Liu","year":"2016","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"M Verso","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"05","key":"ref57","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study","volume":"22","author":"C A Cella","year":"2017","journal-title":"Oncologist"},{"issue":"07","key":"ref58","doi-asserted-by":"crossref","first-page":"e1083","DOI":"10.1634\/theoncologist.2019-0482","article-title":"External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model","volume":"25","author":"A C Spyropoulos","year":"2020","journal-title":"Oncologist"},{"issue":"08","key":"ref59","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-018-0027-8","article-title":"Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer","volume":"118","author":"A J Mu\u00f1oz Mart\u00edn","year":"2018","journal-title":"Br J Cancer"},{"issue":"11","key":"ref60","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"K M Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"I Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"issue":"07","key":"ref62","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/S2352-3026(18)30067-X","article-title":"Simplicity versus complexity: an existential dilemma as risk tools evolve","volume":"5","author":"A A Khorana","year":"2018","journal-title":"Lancet Haematol"},{"issue":"10","key":"ref63","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated Thrombosis Study","volume":"22","author":"G T Gerotziafas","year":"2017","journal-title":"Oncologist"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.sla.0000193959.44677.48","article-title":"A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project","volume":"243","author":"G Agnelli","year":"2006","journal-title":"Ann Surg"},{"issue":"S 01","key":"ref65","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.3747\/co.2008.177","article-title":"Cancer-associated thrombosis: prevention and treatment","volume":"15","author":"K MJ Brose","year":"2008","journal-title":"Curr Oncol"},{"issue":"10","key":"ref66","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"D Farge","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"ref67","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/jth.12725","article-title":"Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH","volume":"12","author":"A A Khorana","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"S 02","key":"ref69","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0049-3848(10)70028-1","article-title":"Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management","volume":"125","author":"M Mandal\u00e0","year":"2010","journal-title":"Thromb Res"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"D Farge","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref71","first-page":"803","article-title":"Prevention of thrombosis in gynecology: double-blind comparison of low molecular weight heparin and unfractionated heparin [in German]","volume":"49","author":"L Heilmann","year":"1989","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"03","key":"ref72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-0038-1655988","article-title":"Blood coagulation and thrombosis in patients with ovarian malignancy","volume":"77","author":"G F von Tempelhoff","year":"1997","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref73","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/SLA.0000000000000340","article-title":"A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer","volume":"259","author":"M C Vedovati","year":"2014","journal-title":"Ann Surg"},{"issue":"08","key":"ref74","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jth.14824","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis","volume":"18","author":"N van Es","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref75","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"M Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"01","key":"ref76","first-page":"92","article-title":"Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy","volume":"63","author":"D L Clarke-Pearson","year":"1984","journal-title":"Obstet Gynecol"},{"issue":"01","key":"ref77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjmed.2013.09.015","article-title":"Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer","volume":"127","author":"M Carrier","year":"2014","journal-title":"Am J Med"},{"issue":"10","key":"ref78","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/bloodadvances.2020001804","article-title":"Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial","volume":"4","author":"J I Zwicker","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"ref79","first-page":"1181","article-title":"Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"M B Streiff","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","author":"A J Mu\u00f1oz Mart\u00edn","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"17","key":"ref81","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1200\/JCO.2013.53.5336","article-title":"Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study","volume":"32","author":"J I Zwicker","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"M Levine","year":"1994","journal-title":"Lancet"},{"issue":"17","key":"ref83","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"G H Lyman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5144\/0256-4947.2015.95","article-title":"Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline","volume":"35","author":"F Al-Hameed","year":"2015","journal-title":"Ann Saudi Med"},{"issue":"17","key":"ref85","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"B A Hutten","year":"2000","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9343(01)00840-3","article-title":"Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy","volume":"111","author":"C Luk","year":"2001","journal-title":"Am J Med"},{"issue":"06","key":"ref87","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.thromres.2008.09.002","article-title":"Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials","volume":"123","author":"M L Louzada","year":"2009","journal-title":"Thromb Res"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00325481.2021.1955542","article-title":"A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment","volume":"133","author":"E J Brea","year":"2021","journal-title":"Postgrad Med"},{"issue":"12","key":"ref89","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"F I Mulder","year":"2020","journal-title":"Blood"},{"issue":"20","key":"ref90","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref91","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"02","key":"ref92","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"R D McBane II","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"17","key":"ref93","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"01","key":"ref94","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1002\/onco.13596","article-title":"Update on guidelines for the management of cancer-associated thrombosis","volume":"26","author":"M B Streiff","year":"2021","journal-title":"Oncologist"},{"issue":"11","key":"ref95","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/ajh.25604","article-title":"Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism","volume":"94","author":"W E Wysokinski","year":"2019","journal-title":"Am J Hematol"},{"issue":"01","key":"ref96","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12959-021-00326-2","article-title":"The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines","volume":"19","author":"N S Alsubaie","year":"2021","journal-title":"Thromb J"},{"issue":"06","key":"ref97","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1538-7836.2010.03892.x","article-title":"Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study","volume":"8","author":"V V Kakkar","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref98","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1538-7836.2009.03301.x","article-title":"AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery\u2013TREK: a dose-ranging study","volume":"7","author":"M R Lassen","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref99","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"G Agnelli","year":"2012","journal-title":"N Engl J Med"},{"issue":"06","key":"ref100","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial","volume":"293","author":"J-N Fiessinger","year":"2005","journal-title":"JAMA"},{"issue":"02","key":"ref101","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"A YY Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"ref102","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"G Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"04","key":"ref103","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"S R Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"issue":"12","key":"ref104","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"R D Hull","year":"2006","journal-title":"Am J Med"},{"issue":"07","key":"ref105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"A YY Lee","year":"2015","journal-title":"JAMA"},{"issue":"09","key":"ref106","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"G Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref107","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"03","key":"ref108","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1055\/s-0041-1736037","article-title":"Management of cancer-associated thrombosis: unmet needs and future perspectives","volume":"5","author":"A Falanga","year":"2021","journal-title":"TH Open"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12959-019-0196-6","article-title":"Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill","volume":"17","author":"B Brenner","year":"2019","journal-title":"Thromb J"},{"issue":"22","key":"ref110","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy","volume":"3","author":"H Al-Samkari","year":"2019","journal-title":"Blood Adv"},{"issue":"07","key":"ref111","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/jth.14468","article-title":"Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: an analysis of thrombotic and bleeding outcomes","volume":"17","author":"J R Shaw","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref112","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3747\/co.25.4266","article-title":"Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus","volume":"25","author":"M Carrier","year":"2018","journal-title":"Curr Oncol"},{"issue":"04","key":"ref113","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jval.2017.09.015","article-title":"What impact does venous thromboembolism and bleeding have on cancer patients' quality of life?","volume":"21","author":"A J Lloyd","year":"2018","journal-title":"Value Health"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"A T Cohen","year":"2017","journal-title":"Thromb Haemost"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758856.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T23:30:56Z","timestamp":1673134256000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":113,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,1,7]]},"published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758856","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"type":"electronic","value":"2512-9465"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}